PubMed Health⌕ Search

Biomedical subjects

J P Karr

Publications and source records attributed to J P Karr.

16 recordsLinked to original sources
PubMed1987

The possibility of aromatization of androgen in human prostate.

Aromatase in human prostate tissue was determined in homogenized human prostate (three BPH and two normal specimens) incubated with [1-beta-3H]androstenedione (radiometric method) or [1,2,6,7-3H]androstenedione (estrogen production analysis method) in the presence of NADPH. Using the former procedure, significant amounts of 3H2O, resulting from the release of 3H at the C-1 position during aromatization, were measured and these increased with incubation time and amount of tissue, whereas the amount of estrone and estradiol-17 beta resulting from the latter method and calculated from the 3H/14C ratio in preparations of purified crystal was very small. The preliminary results, which suggest that an androgen aromatase system exists in the human prostate, point to the need to further investigate the identity and properties of the metabolic products resulting from the conversion of androgen to estrogens and other metabolites.

Androstenedione↗
PubMed1985

The antigenic relatedness of proteins from human and simian prostate fluid.

Two-dimensional electrophoretic analysis of human prostate fluid reveals an abundant protein migrating to a molecular weight of 15 kD and an isoelectric point of 5.5. Polyclonal antibodies were raised specifically to microgram quantities of electrophoresed, excised, and eluted PSP15 (prostate secretory protein). Western immunoblot analysis using these antibodies showed they not only react to PSP15, but cross-react with simian prostate and human seminal fluid proteins of similar molecular weights. Two-dimensional gel immunoblots strongly suggest that the seminal protein and PSP15 are the same, thereby providing a more accessible source of the protein. The antibody to the human PSP15 cross-reacted with neither prostate fluid from the ventral lobe of the rat prostate nor the prostate fluid from the beagle dog.

Animals↗
PubMed1979

Steroid hormone receptors in the prostate.

Specific receptors for dihydrotestosterone and estradiol-17-beta have been identified in cytosols of the human and baboon prostate. Binding of radioactive estradiol-17-beta to the 0.4 M potassium chloride extractable component of human prostate nuclei also was demonstrated. Cyproterone acetate and diethylstilbestrol, agents of known high affinity for dihydrotestosterone and estradiol-17-beta receptors, respectively, did not bind significantly to sex hormone binding globulin and, therefore, were useful as competitors in distinguishing binding of dihydrotestosterone and estradiol-17-beta to sex hormone binding globulin and to their specific receptors. Displacement of [3H]-estradiol-17-beta binding by diethylstilbestrol in cytosols of 11 needle biopsy specimens (mean equals 16.8 mg.) from prostatic cancer patients was analyzed. These preliminary data indicated a trend towards greater competition by diethylstilbestrol for high affinity binding sites in differentiated tumor specimens from men who were not receiving estrogen therapy. Objective and subjective responses to hormone therapy were recorded in these patients, whereas the disease in those men with low displacement assay values progressed.

Aged↗
PubMed1979

Androgen binding in the baboon prostate.

Androgen receptors were identified and partly characterized in cytosols of the caudal and cranial prostatic lobes of a 24-hr castrate baboon. Binding of cyproterone acetate (CA) to testosterone-binding globulin (TeBG) in baboon serum was negligible and therefore was an appropriate unlabeled competitor for distinguishing high-affinity binding of tritiated dihydrotestosterone (3H-DHT) to serum contaminants and receptors in cytosol preparations when multiple-point saturation analyses and removal of free steroid by charcoal adsorption were used. Specificity of androgen binding was demonstrated by the inability of diethylstilbestrol, a synthetic estrogen known to have low binding affinity for TeBG, to displace 3H-DHT from the receptor protein. The number of high-affinity binding sites and the dissociation constant of the androgen receptor calculated for the caudal lobe were 102 fmoles/mg cytosol protein and 4.0 X 10(-9) M, respectively; corresponding values for the cranial lobe were 49 fmoles and 1.3 X 10(-9) M.

Animals↗
PubMed1978

Sex hormone binding globulin and transcortin in human and baboon males.

TeBG and transcortin were identified in serum from adult male baboons. TeBG values were higher than the TeBG concentration in adult men. The relative competitive abilities of three natural steroids, a synthetic androgen and two synthetic estrogens, for binding sites on TeBG occupied by radioactive DHT were compared. At a 10-fold molar excess, using both baboon and human TeBG, DHT and T were the most effective competitors; E2 was intermediate and DES a very poor one. Using gel filtration, the transcortin concentrations (mg/L) in two baboons were 16.8 and 27.4; the normal range for men is 23--45. The serum transcortin value of a third baboon, determined by equilibrium dialysis, was 0.41 micron/L (21.5 mg/L). Competition studies, using both techniques, showed that progesterone has a slightly higher affinity for baboon transcortin than cortisol and that a synthetic progestin does not bind to transcortin. Plasma binding capacity for synthetic steroids should be tested before they are used for studies on specific tissue receptors contaminated with serum.

Animals↗
PubMed1977

Development of interspecific hybrids of Mus.

Artificial insemination has been used to produce interspecific mouse hybrids. Mus musculus x Mus cervicolor cervicolor hybrids failed to complete more than a few cleavage divisions but both M. musculus x M. dunni and M. musculus x M. caroli hybrids completed preimplantation development. These hybrid embryos are heterozygous for various X-linked enzymes and may provide a useful genetic system for studying X-chromosome inactivation during early development. Further development of M. muscuius x M. caroli hybrids was studied: several completed foetal development; a few survived to maturity but none has yet reproduced.

Animals↗
PubMedDate not supplied

The potential significance of aromatase in the etiology and treatment of prostatic disease.

Prior to the present conference on aromatase, reports in the literature on prostatic aromatase have been scattered over time, few in number, and the results have been widely divergent. Moreover, several participants at this conference have reported unpublished data that failed to detect the existence of androgen aromatase in the prostate of man and other species. While papers and posters presented at this conference have added new information to this field, there would still appear to be no consensus as to the biological significance, if any, of the putative androgen aromatase system or the practical importance of inhibitors of prostatic and/or peripheral aromatase as a treatment modality for benign prostatic hyperplasia (BPH). Thus, it would be difficult to predict at this time the ultimate impact which current prostatic aromatase investigations will eventually have on our understanding and treatment of prostatic disease. To summarize the status of our current understanding of aromatase as it relates to prostatic function and disease, it would be safe to note that this field is virtually wide open for researchers to explore, both in terms of the future role that aromatase inhibitors may have in clinical investigations and in terms of the functional significance of aromatase, if any, in the normal prostate as well as in the pathogenesis of BPH and prostate cancer. Clearly, the widely divergent results currently available in the literature must reflect, in part, differences in methodology, anatomy, tissue types, the relative amounts of stroma and epithelium in specimens analyzed, the cellular and tissular (normal, BPH, and carcinomatous) heterogeneity encountered in clinical specimens, and the pharmacologic features of aromatase inhibitors tested.

Aromatase↗
PubMedDate not supplied

Some new approaches to potential test systems for drugs against prostatic cancer.

We have previously reported on test systems, based on 5alpha-reductase (5alpha-RA) and arginase activities and steroid deposition in animal prostates, potentially useful in screening drugs possibly effective in cancer of the prostate. Recently, we have concentrated on the development of other in vivo and in vitro systems which may prove of further value in testing such drugs. These systems include the following: (a) The effects of drugs on 5alpha-RA activity in human and animal non-malignant and human cancerous prostatic tissues in organ culture. The parameters necessary for the maintenance of optimal 5alpha-RA in such explants have been determined, and it has been shown that certain agents (estramustine phosphate, progesterone, estradiol-17beta) can inhibit 5alpha-RA under in vitro conditions, pointing to the potential use of such an approach in screening various cytostatic agents. In addition, 65Zn deposition, the histology, and the androgen metabolism in such tissues in organ culture are being determined as additional parameters. (b) The deposition of 65Zn in the rat dorsolateral gland, particularly as affected by prolactin and testosterone, and the effects of chemotherapeutic agents on such deposition. Methotrexate and CCNU have been shown to be potent inhibitors of 65Zn deposition in the dorsolateral gland. The parameters related to zinc metabolism in the prostate are being further investigated. (c) The demonstration of receptors for estrogens (estradiol-17beta, diethylstilbestrol) in the prostate of the baboon. The various parameters related to the specificity of such receptors have been established. The development and standardization of these approaches, some facets of which are reported in the present publication, may prove them to be more sensitive, specific, and optimal than other systems and should afford an opportunity to test various combinations of drugs potentially useful in cancer of the prostate with relative speed, efficacy, and ease of manipulation.

Adrenalectomy↗